Ilumya Market Report 2026

Ilumya Market Overview

• The Ilumya market growth in the historic period has been driven by limitations of topical psoriasis treatments, rising prevalence of chronic plaque psoriasis • Market expansion is supported by increasing biologic penetration in dermatology, growth in systemic psoriasis therapies • Growth Driver: Impact Of Rising Psoriasis Prevalence On The Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ilumya Market?

Ilumya is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy (ultraviolet light treatment). It is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammation and the overproduction of skin cells associated with psoriasis. By inhibiting IL-23, Ilumya helps reduce inflammation and slow the rapid turnover of skin cells, improving the symptoms of psoriasis such as plaques, scaling, and redness. The main patient demographics of ilumya include pediatric patients and adult patients. Pediatric patients refer to individuals under the age of 18 who require medical care for various health conditions. It is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is applied for plaque psoriasis, psoriatic arthritis, and other inflammatory conditions.

What Is The Ilumya Market Growth Forecast?

The growth in the forecast period can be attributed to increasing biologic penetration in dermatology, growth in systemic psoriasis therapies, expanding insurance coverage for biologics, advancements in cytokine selective treatments, rising patient adherence programs. Major trends in the forecast period include growth of il-23 inhibitor adoption, shift toward long acting psoriasis therapies, rising demand for biologic dermatology treatments, improved dosing convenience, expansion of moderate to severe psoriasis care.

Global Ilumya Market Segmentation

1) By Patient Demographics: Pediatric Patients, Adult Patients 2) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies 3) By Application: Plaque Psoriasis, Psoriatic Arthritis, Other Inflammatory Conditions

What Are The Drivers Of The Ilumya Market?

The growing prevalence of psoriasis is expected to propel the growth of the ilumya market going forward. Psoriasis is a long-term autoimmune condition that accelerates skin cell growth, resulting in red, scaly patches on the skin. The growing prevalence of psoriasis can be attributed to a combination of better diagnosis and awareness, environmental factors, genetic predisposition, obesity, and the impact of certain medications and infections. Ilumya is required for psoriasis as it helps reduce inflammation and slow the overproduction of skin cells by targeting interleukin-23 (IL-23), effectively managing the symptoms of moderate to severe plaque psoriasis. For instance, in May 2023, according to a report published by the National Library of Medicine (NLM), a US-based medical library, it is predicted that the incidence and DALY numbers of psoriasis will increase among individuals aged 30-39 to 2030. Therefore, the growing prevalence of psoriasis is driving the growth of the ilumya industry. The increasing healthcare expenditure is expected to propel the growth of the ilumya market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Increasing healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, and higher demand for healthcare services. Healthcare expenditure on Ilumya focuses on advanced treatments for moderate-to-severe plaque psoriasis, targeting interleukin-23 (IL-23). For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the ilumya industry. The increasing funding of clinical trials is expected to be propelling the growth of the Ilumya market going forward. Clinical trials funding refers to the financial resources allocated to support research studies that evaluate the safety, efficacy, and therapeutic potential of new medical treatments and interventions. The rise in clinical trials funding is due to the growing recognition of the need for innovative therapies to address unmet medical needs in chronic inflammatory conditions and the commitment of governments and organizations to advance medical research. Ilumya benefits from clinical trials funding by enabling comprehensive research into biologic therapies for moderate-to-severe plaque psoriasis, supporting evidence-based treatment protocols, and facilitating the development of next-generation dermatological solutions. For instance, in December 2024, according to The Association of the British Pharmaceutical Industry, a UK-based organization, total number of industry-sponsored clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023, supporting the development of new patient treatments and generating additional revenue for the NHS. Therefore, the growing funding of clinical trials is driving the growth of the Ilumya industry.

Key Players In The Global Ilumya Market

Major companies operating in the ilumya market are Sun Pharmaceutical Industries Ltd

Regional Insights

North America was the largest region in the ilumya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ilumya Market?

The ilumya market consists of sales of biologics and biosimilars, dermatology products, and generic pharmaceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ilumya Market Report 2026?

The ilumya market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ilumya industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.